Shots:
- J&J has reported the long-term data from the QUASAR LTE trial in pts with mod. to sev. active ulcerative colitis, showing lasting disease control for patients
- The P-IIb/III (QUASAR) trial assessed Tremfya (IV induction: 200mg Q4W; SC maintenance: 100mg, Q8W or 200mg, Q4W) vs PBO in UC pts
- At Wk. 140, ~89% completed treatment, with 80.8% pts on Tremfya were in clinical remission, 78.6% achieved HEMI & 53.6% were in endoscopic remission; most pts who achieved clinical remission were steroid-free at ≥8wks., while 87.5% of Wk. 44 responders maintained remission through Wk. 140
Ref: PRnewswire | Image: J&J | Press Release
Related News: J&J Reports P-III Trial Outcomes Showing Tecvayli Monotherapy Extends PFS and OS in R/R Multiple Myeloma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
